Prostaglandin E2 signals through PTGER2 to regulate sclerostin expression.

Area of Science:

• Bone biology
• Endocrinology
• Molecular signaling

Background:

• Wnt signaling pathway regulates skeletal homeostasis.
• Sclerostin (Sost) is a Wnt antagonist; its loss increases bone mass.
• Prostaglandin E(2) (PGE(2)) affects osteoblasts and osteoclasts.

Purpose of the Study:

• To investigate the effect of PGE(2) on Sclerostin expression in osteoblastic cells.
• To elucidate the signaling pathway mediating PGE(2)'s effect on Sost.
• To determine the role of the PGE(2) receptor EP2 in this process.

Main Methods:

• Treatment of UMR106.01 osteoblastic cells with PGE(2).
• Analysis of Sclerostin (Sost) and Wnt/TCF target gene expression (Axin2, Tcf3).
• Investigation of the cyclic AMP/PKA pathway and EP2 receptor involvement using agonists and siRNA.

Main Results:

• PGE(2) significantly decreased Sclerostin expression in osteoblastic cells.
• Reduced Sost expression correlated with increased Wnt/TCF target gene expression.
• The suppressive effect of PGE(2) on Sost was mediated by the cyclic AMP/PKA pathway and the EP2 receptor.

Conclusions:

• Prostaglandin E(2) inhibits Sclerostin expression in osteoblasts.
• This inhibition is linked to the activation of the cyclic AMP/PKA pathway via the EP2 receptor.
• These findings reveal a functional link between prostaglandins and the Wnt/β-catenin signaling pathway in bone metabolism.